Strides Pharma International AG
Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
more
Stories about Schweiz
- Language:
- Media:
- Period:
- Period:Total
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
moreDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
moreGlobalance launches Globalance World - a digital, interactive globe for sustainable investments
Zurich (ots) - Globalance Bank, pioneer in sustainable investing is launching Globalance World, a world first in the form of a digital and interactive globe for sustainable investments. At www.globalanceworld.com, investors and other finance enthusiasts have free access to analyze and assess the future orientation and sustainability of currently over 6,000 listed ...
moreSwiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
moreEvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...
moreWe+Care: EUR1.5 million to increase the quality at the end of life
moreNZZ Media Group: Audienzz acquires Zulu5 for more transparency and quality in the digital advertising market
morePatent nullification proceedings of Avonisys against Synova at the Swiss Federal Patent Court
moreBacula Systems Receives Backup and Recovery Deduplication Patent
moreEight new Greater Zurich Honorary Ambassadors
moreVersameb raises CHF 6.4 million in Seed C round and strengthens the team
Basel (ots) - Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs. The proceeds of this financing round will be used to expand ...
moreQCAM Currency Asset Management AG
Currency Asset Management doyen Gary Klopfenstein strengthening QCAM's international market growth plans
more
1